$ADRX SEC Filings

Filed On	Filing
16 Oct 2026	SCHEDULE 13G
05 Oct 2026	SCHEDULE 13D
02 Oct 2026	SCHEDULE 13D
01 Oct 2026	SCHEDULE 13G
30 Sep 2026	Form 4: Chimovits Erez, Director Received 9,230,509 shares by conversion · Bought 61,516 shares ($1.05M)
30 Sep 2026	Form 4: Gordon Carl L, Director Received 23,255,789 shares by conversion · Bought 950,000 shares ($16.2M)
30 Sep 2026	Form 4: Orbimed Advisors Llc, Director and 4 others Received 23,255,789 shares by conversion · Bought 950,000 shares ($16.2M)
29 Sep 2026	Form 4: Lav Biosciences Fund V, L.p., 10% owner and 2 others Received 11,858,655 shares by conversion
29 Sep 2026	Form 4: Sr One Capital MANAGEMENT, Llc, 10% owner Received 8,336,661 shares by conversion · Bought 1,600,000 shares ($27.2M)
29 Sep 2026	Form 4: George Simeon, Director Received 8,336,661 shares by conversion · Bought 1,600,000 shares ($27.2M)
28 Sep 2026	424B4
28 Sep 2026	Form 4: MacLeod Alan Robert, Chief Scientific Officer Granted 170,692 Employee Stock Option (right to buy)
28 Sep 2026	Form 4: Zhu Rui (NMN), Chief Technology Officer Granted 512,076 Employee Stock Option (right to buy)
28 Sep 2026	8-K: Unregistered Sales of Equity Securities; Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year +1 more ADARx Pharmaceuticals, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that:
28 Sep 2026	Form 4: Ackles Robert William, Chief People Officer Granted 85,346 Employee Stock Option (right to buy)
28 Sep 2026	Form 4: Fisk Ryan, CFO and CBO Granted 170,692 Employee Stock Option (right to buy)
28 Sep 2026	Form 4: Li Zhen, Director Granted 1,024,152 Employee Stock Option (right to buy)
28 Sep 2026	S-8
24 Sep 2026	EFFECT
24 Sep 2026	Form 3: MacLeod Alan Robert, Chief Scientific Officer

Comments